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Background: APOBEC3 proteins are host factors that restrict infection by retroviruses like HIV, MMTV, and MLV and
are variably expressed in hematopoietic and non-hematopoietic cells, such as macrophages, lymphocytes, dendritic,
and epithelia cells. Previously, we showed that APOBEC3 expressed in mammary epithelia cells function to limit
milk-borne transmission of the beta-retrovirus, mouse mammary tumor virus. In this present study, we used
APOBEC3 knockout mice and their wild type counterpart to query the role of APOBEC3 in sexual transmission of
LP-BM5 MLV – the etiological agent of murine AIDs (mAIDs).
Results: We show that mouse APOBEC3 is expressed in murine genital tract tissues and gametes and that genital
tract tissue of APOBEC3-deficient mice are more susceptible to infection by LP-BM5 virus. APOBEC3 expressed in
genital tract tissues most likely plays a role in decreasing virus transmission via the sexual route, since mice deficient
in APOBEC3 gene have higher genitalia and seminal plasma virus load and sexually transmit the virus more
efficiently to their partners compared to APOBEC3+ mice. Moreover, we show that female mice sexually infected
with LP-BM5 virus transmit the virus to their off-spring in APOBEC3-dependent manner.
Conclusion: Our data indicate that genital tissue intrinsic APOBEC3 restricts genital tract infection and limits sexual
transmission of LP-BM5 virus.
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Viruses that use the genital mucosa as a portal of entry
into the host include HPV, HSV, hepatitis B virus, and
retroviruses like SIV, MLV, and HIV. Worldwide, HIV
infection is pandemic in many countries and is primarily
transmitted from infected persons to their sexual part-
ners through contact with infected semen and vaginal
secretions [1-4]. The control of sexual transmission is,
therefore, pivotal to curbing the HIV pandemic, espe-
cially since the genital tract may also serve as a sanctu-
ary in which HIV undergoes selective pressures [5-8]
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reproduction in any medium, provided the orvariants that may be sexually transmitted [9-11]. Indeed,
it is known that patients with highly active anti-
retroviral therapy (HAART) - suppressed plasma viral
load continue to shed viral RNA through the genital
tract [12,13]. It is therefore critical to determine whether
host factors can control virus replication and evolution
within the male genital tract. Since we could not use
human subjects for these experiments, a mouse model
offers a practical alternative. Hence, we utilize the mur-
ine acquired immunodeficiency syndrome (mAIDs)
model.
mAIDs is a mouse retroviral disease caused by the
viral complex LP-BM5 [14]. LP-BM5 is a mixture of
murine leukemia viruses comprised of the replication
competent helper virus BM5e, the mink cell cytopathic
focus-inducing virus, and the replication-defective virustd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Infection of susceptible mice with LP-BM5 causes severe
immunodeficiency syndrome similar to human AIDS
[14,17]. Some of the similar characteristics between
mAIDS and hAIDS include hypergammaglobulinemia,
lymphadenopathy, severely depressed T- and B-cell
responses to mitogens, increased susceptibility to infec-
tion, disease progression and the development of B-cell
lymphomas and splenomegaly [18-22]. Despite the simi-
larities between mAIDS and hAIDS, differences between
the two infectious diseases exist. Unlike human AIDS,
mice suffering from mAIDS develop mediastinal lymph
node enlargement and may die of respiratory failure
[23]. Propagation of mAIDS in mice requires the matrix
(MA) and p12 of the Gag gene of BM5def [24]. Due to
the similarity in virus transmission and disease outcome
between LP-BM5- and HIV infections, mAIDs is a good
model for examining sexual transmission of HIV and
have been used for the initial evaluation of new drugs
[25-29].
To be transmitted sexually, HIV and LP-BM5 will have
to overcome host resistance in genital mucosal surfaces
which are composed of different types and layers of epi-
thelial cells and mucosa-associated lymphoid tissues
(MALTs). The male and female genital mucosal layers
are filled with cells of the immune system, including
dendritic cells (DCs), macrophages and lymphocytes
[30-36]. The immune cells in the genital mucosal sur-
faces express pattern recognition receptors (PRRs) such
as Toll-like receptors, RIG-I-like receptors, and NOD-
like receptors [37-40] that function to recognize differ-
ent pathogen associated molecular patterns (PAMPs)
and stress signals leading to activation of the host innate
and adaptive immune responses. Aside from innate and
adaptive immune responses elicited by cells in the geni-
tal mucosal surfaces, the expression of anti-viral genes
such as APOBEC3 (A3) in male reproductive organs has
been reported [41,42].
A3 proteins are virus restriction factors that encode
DNA-editing enzymes. The human genome encodes 7
A3 genes (A3 –A, -B, -C, -D/E, -F, -G, -H), and the
mouse genome encodes only 1 A3 gene [43]. A3 pro-
teins are variably expressed in hematopoietic and non-
hematopoietic cells, and in different tissues [42,44-47].
The most studied human A3 genes (A3G and A3F) and
mouse A3 (mA3) are reported to confer intrinsic im-
munity to HIV-1 and other viruses including MMTV
and MLV [45-52]. In the absence of HIV-1 viral infectiv-
ity factor (Vif ), A3F and A3G are packaged into progeny
virions via interactions with the nucleocapsid (NC) pro-
tein and viral RNA. A3 proteins then inhibit infection in
target cells by deaminating deoxycytidine residues on
the DNA minus strand following reverse transcription
and inducing mutations in newly synthesized HIV-1DNA. In addition, A3F and A3G degrade reverse tran-
scribed viral DNA prior to integration and induce muta-
tion of viral genes in the integrated provirus [53-56].
However, in the presence of Vif, A3F and 3G are marked
for proteasomal degradation [57-59], thus preventing
their packaging into progeny virions; resulting in pro-
ductive infection of target cells. Furthermore, there is
growing evidence that A3 proteins can restrict HIV and
other viral infection in a deamination independent man-
ner [45,46,60,61]. We previously showed that endogen-
ous mA3 restricts MMTV infection in vivo in a
deamination independent mechanism [45]. In addition
to limiting virus replication, we recently demonstrated
that the rate of milk-borne transmission of MMTV was
significantly increased in mice harboring targeted muta-
tion in the mA3 gene [47], demonstrating that A3 pro-
teins play a role in containing milk-borne virus
transmission.
In the present study, we define the role of A3 in sexual
transmission of retroviruses using the mAIDs model and
mice with targeted mutation in the mA3 gene. Our data
indicate that mice with targeted mutation of APOBEC3
gene have a higher rate of sexual transmission compared
to the wild type control, suggesting a role for APOBEC3
in limiting sexual transmission.
Results
mA3 is expressed in genital tract tissues and gametes
Healthy female and male C57BL/6 mice were eutha-
nized, and different genital tract tissues and gametes
were obtained for analysis of mA3 mRNA levels by real-
time quantitative PCR (qPCR). We observed that mA3 is
expressed at varying levels in male (Figure 1A and 1B)
and female (Figure 1C and 1D) genital tissues and
gametes. In males, the epididymis and seminal glands
have the highest level of mA3 expression, while the
prostate gland, penis and spermatozoa have lower levels
of mA3 expression (Figure 1B). The distribution of mA3
in female genital tissues shows that the cervix and mam-
mary gland have the highest levels of expression while
the oviduct, clitoral gland, uterine horn, and vagina ex-
press lower levels of mA3 mRNA (Figure 1D). Although
both male and female reproductive organs express mA3
mRNA, male organs such as epididymis, seminal gland,
testis, and vas deference make more mA3 transcripts
than any female organ tested.
mA3-deficient mice have increased susceptibility to acute
LP-BM5 infection
Since male genital organs and gametes express mA3,
and since we previously showed that mA3 deficient mice
are more susceptible to MLV and MMTV [45,46,51,52],
we hypothesize that mice lacking the mA3 gene (mA3-/-)
will have higher virus load upon infection with LP-BM5
Figure 1 mA3 is expressed in murine female and male reproductive organs. Age-matched male and female WT mice on C57BL/6
background were sacrificed. At necropsy, tissue samples were obtained for RNA extraction. RNA was reverse transcribed and the resulting cDNA
was used to examine levels of mA3 transcript by endpoint PCR (A and C) and real-time quantitative PCR (B and D). Data were normalized to
GAPDH and presented as relative levels to splenic mA3 mRNA. Error bars are standard error; * is significance with p value equal or less than 0.05;
and ** is significance with p value equal or less than 0.01. Experiment was performed 3 times with similar results.
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(WT) and mA3-/- mice with LP-BM5 virus subcutaneously
(SubQ) on the footpad or intraperitoneally (IP). Footpad
infected mice were sacrificed weekly for 4 weeks while IP
infected mice were sacrificed at weeks 3 and 4 (Figure 2A).
Spleen and testes (IP infected) or lymph nodes (SubQ
infected) were used to examine the level of infection by
qPCR. We detected significantly higher levels of LP-BM5
DNA in the lymph nodes of mA3-/- mice compared to
the WT controls (Figure 2B). Lymph nodes were infected
as early as 1 week post inoculation, and virus load
increased in a time dependent manner. Examination of
the spleen (Figure 2C) and testes (Figure 2D) for proviral
DNA at 3 and 4 weeks after infection showed a signifi-
cant and time dependent increase in virus load in mA3-
/- mice compared to the WT. We did not observe
spleen or testes infection at weeks 1 and 2 following in-
oculation. To determine whether mA3 edits LP-BM5
genome, we generated and analyzed sequences of LP-
BM5 from total cellular DNA obtained from spleens and
testes of infected male mice. Analysis of LP-BM5 se-
quence data showed no evidence of hypermutation (data
not shown).mA3 deficiency exacerbates mAIDs-associated lympho-
proliferation and splenomegaly
Since C57BL/6 mice infected with LP-BM5 develop
chronic splenomegaly, we predicted that loss of mA3
will result in severe splenomegaly. Age and weight
matched WT, mA3+/-, and mA3-/- mice infected with
LP-BM5 (Figure 3A) were examined for the develop-
ment of splenomegaly. In general, gross appearance and
size of the spleen were variable. mA3-/- mice show se-
vere splenomegaly because their spleen sizes and weights
were profoundly larger compared to the heterozygotes
and WT controls in that order (Figure 3B and 3C). Al-
though the spleens of infected mA3-/- mice were much
larger than that of the WT, the WT spleen weights
were significantly higher compared to the naïve mice
(Figure 3B and 3C). Since most of the cells infected by
LP-BM5 virus belong to the lymphocyte lineage [62,63]
and the infected B and T cells greatly expand [62-65], we
examined the percentage of B220+ and CD4+ expressing
splenocytes using flow cytometry. LP-BM5 infection
caused significant increase in B220 and CD4 expressing
cells in mA3-dependent manner (Figure 3D to 3F).
The percentage of B220 splenocytes were 25.8 ± 0.1;
Figure 2 Mice deficient in APOBEC3 gene are more susceptible to acute LP-BM5 virus infection. Age and weight-matched WT and
mA3-/- mice on C57BL/6 background (n = 5) were inoculated with LP-BM5 virus subcutaneously (SubQ) on the right hind footpad or via
intraperitoneal (IP) route (A). Mice were sacrificed at different time frames as shown on the figures. At necropsy, lymph nodes were collected
from SubQ infected mice, while spleens and testes were obtained from IP infected mice. DNA was isolated from the different tissues and
subjected to quantitative PCR (qPCR) to determine level of LP-BM5 infection in lymph nodes (B) spleen (C), or Testes (D). All qPCR data were
normalized to GAPDH and presented as relative levels. Error bars are standard error; * is significance with p value equal or less than 0.05; and
** is significance with p value equal or less than 0.01. Experiments were repeated five different times with similar results.
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naïve WT, naïve mA3-/-, WT, mA3+/-, and mA3-/-
mice in that order (Figure 3D). A similar observation
was made upon examination of CD4+ T cells. The
percentage of CD4+T cells increased from 38.6 ± 1.8
in WT mice to 50.7 ±4.4 in mA3-/- (Figure 3D). We
also evaluated the expression of CD69 by B220+ B
and CD4+ T cells after infection with LP-BM5. The
percentage of B220+ cells expressing CD69 expanded
from 4.77%/4.29% in naïve WT/mA3-/- mice to 14.8%,
17.6%, and 22.2% in WT, mA3+/-, and mA3-/-
infected mice in that order (Figure 3G). A similar ob-
servation was made on CD4+ T cells expressing CD69.
The percentage of CD4+ T cells expressing CD69
increased from 2.78%/2.44% in naïve WT/mA3-/- mice
to 12.70%, 13.9%, and 21.0% in infected WT, mA3+/-,
and mA3-/- mice respectively (Figure 3H). The expan-
sion of CD69 expressing B220+ and CD4+ T cells has
been previously reported in mice chronically infected
with the LP-BM5 related retroviruses, Friend MLV
[66] and MMTV [67].
Mice lacking mA3 gene have higher genital infection and
seminal plasma virus load
The presence of HIV-1 virions in human seminal plasma
and seminal vesicles has been demonstrated [68-72]. To
examine the impact of mA3 on virus titre and the linkto sexual transmission, we examined viral load in the
testes, purified spermatozoa and seminal plasma
obtained from the epididymis of WT, mA3+/-, and
mA3-/- mice. Upon evaluation of sperm cells, no differ-
ences in cell morphology were observed prior to sperm
purification (Figure 4A). We also did not observe any
difference in the morphology of spermatozoa after puri-
fication (Figure 4B). However, sperm cells from mA3-/-
mice were significantly infected with LP-BM5 virus
compared to the heterozygote and WTcontrols (Figure 4C).
A similar observation was made in testicular DNA obtained
from mA3-/- mice (Figure 4D). A comparison of viral
RNA (vRNA) in cell-free seminal plasma as measured by
qPCR showed high level of vRNA present in seminal
plasma of mA3-/- (Figure 4E). To confirm that LP-BM5
MLV is present in genital tissues and seminal plasma, we
used Western blot to detect viral capsid protein (p30) in
these samples. The testicular cells and seminal plasma of
mA3-/- mice have higher viral p30 protein (Figures 4F
and 4G) compared to mA3+/- and WT counterparts.
There appears to be a different banding pattern in mA3-/-
lane for αp30. This banding pattern was seen with each
experiment, but it is not clear why the difference and if
the band is a doublet or a larger amount of the p30. Re-
gardless, the high viral RNA and protein observed in
mA3-/- mice indicate that these mice are more highly
infected, and that their seminal plasma contains more
Figure 3 Lympho-proliferation and splenomegaly are more pronounced in mA3 deficient mice. Age and weight-matched WT, mA3+/-,
and mA3-/- male mice on C57BL/6 background (n = 5) were inoculated with PBS (negative control) or LP-BM5 virus via the IP route (A). Eight
weeks after inoculation, mice were sacrificed. Spleen sizes (B) and weights (C) were recorded for each genotype. Single cell suspension was
obtained from splenocytes and stained with cell surface antibodies to differentiate B cells from CD4+ T lymphocytes and determine lymphocyte
number using flow cytometry. B cell percentage was detected with anti-B220 (D and E), and CD4+ T percentage was detected with anti-CD4 (D
and F). Activation of CD69 expression on B cells (G) and CD4+ T cells (H) was detected upon triple-staining with anti -B220, -CD4, and -CD69.
Flow cytometry data were analyzed with Flowjo. Error bars are standard error; * is significance with p value equal or less than 0.05; and ** is
significance with p value equal or less than 0.01. Experiments were repeated at least three different times with similar results and representative
data presented.
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that the virus prepared from the seminal plasma is devoid
of cellular contamination. To determine whether high
seminal plasma vRNA in mA3-/- mice reflects the infec-
tiousness of virus in the semen, we infected WT spleno-
cytes with a portion of purified cell-free seminal plasma
virus for 24 hours. Seminal plasma virus from mA3-/-
was significantly more infectious than the mA3+/- and
WT controls because splenocytes that were infected with
the mA3-/- virus have about 11 and 12 times more LP-
BM5 DNA than the mA3+/- and WT controls respect-
ively (Figure 4H). Examination of other genital organs
also reveal that mA3-/- mice harbor significantly higher
viral load (vRNA) compared to the mA3+/- and WT con-
trols (Figure 4I).Loss of APOBEC3 gene facilitates efficient sexual
transmission of LP-BM5
Previous studies have shown that murine genital organs
are susceptible to LP-BM5 infection and that the virus is
transmitted sexually [73]. To evaluate whether mA3
plays a role in sexual transmission of LP-BM5 from male
to female mice, we infected age-matched male WT, mA3
+/-, and mA3-/- mice and mated infected mice with
naïve females of different genotypes. Examination of tes-
ticular and splenic DNA reveals that all male mice were
infected. However, higher levels of infection in the testes
(Figure 5A) and spleen (Figure 5B) were observed in
mA3-/- mice compared to their mA3+/- and WT coun-
terparts. Furthermore, infected male mice transmitted
the virus to their female partners of different genotypes
Figure 4 mA3-/- mice have higher genital infection and more seminal plasma virus load. Age and weight-matched WT, mA3+/-, and
mA3-/- male mice on C57BL/6 background (n = 5) were inoculated with LP-BM5 virus via the IP route. Eight weeks after infection, mice were
sacrificed, and all male reproductive organs obtained. Samples were pooled based on genotype. Spermatozoa and seminal plasma were
extracted from pooled epididymis, and spermatozoa examined for morphology prior to purification (A). Following purification, sperm cells were
also examined for morphology (B). DNA was isolated from spermatozoa (C) and testes (D) and evaluated for level of infection by qPCR. Total RNA
was isolated from a portion (200 μl) of cell-free seminal plasma virus preparation. Equivalent concentration of RNA was reverse transcribed, and
the resulting cDNA subjected to qPCR examination of viral RNA (E). A portion of testes (F) and cell-free seminal plasma virus preparation (G) were
subjected to protein extraction and Western blot with antibodies against MLV capsid (α-p30) and murine GAPDH (α-GAPDH -used to
demonstrate that the cell-free seminal plasma virus preparation devoid of cellular extract). The remaining portion of cell-free seminal plasma virus
preparation was used to infect splenocytes from WT C57BL/6 ex vivo for 24 hours. Infected splenocytes were used for DNA extraction and qPCR
examination of level of infection (H). Total DNA was also isolated from different male reproductive organs. Following reverse transcription of RNA,
the level of viral RNA in these tissues was determined by qPCR (I). Western blot and qPCR data were normalized to GAPDH. Error bars are
standard error; * is significance with p value equal or less than 0.05; and ** is significance with p value equal or less than 0.01. Experiments were
performed at least three different times and similar results were obtained.
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(Figures 5C to 5E) and PBMCs (Figures 5F to 5H) of
naïve females mated with infected mice. Rate of virus
transmission was significantly higher in female mice
mated with mA3-/- males irrespective of the female
mice genotype (Figure 5C and 5F), followed by females
mated with mA3+/- mice (Figure 5D and 5G), then
females mated with WT (Figure 5E and 5H). Since rate
of LP-BM5 replication is highest in mA3-/- mice
(Figures 4E and 4F), we examined the impact of
higher virus replication on sexual transmission. Exam-
ination of virus transmission from WT, mA3+/-, or
mA3-/- infected male to WT females reveals that in-
deed, mA3-/- mice harbor significantly more virions
compared to the mA3+/-, and WT counterparts inthat order (Figure 5I and 5J). This result confirms
that high rate of LP-BM5 replication in mA3-/- mice
translates to high rate of sexual virus transmission.
Female mice sexually infected with LP-BM5 transmit the
virus to their off-spring in APOBEC3-dependent manner
mA3 mediates milk-borne transmission of MMTV from
an infected female to her off-spring [47]. To validate the
role of mA3 in sexual transmission of LP-BM5 virus, we
examined rate of virus infection in the off-springs of
female mice that were sexually infected by their male
partners (Table 1). We found that off-springs of sexually-
infected female mice of different genotypes are infected
and that level of infection depends on the presence or ab-
sence of mA3 gene. Thus, mA3-/- off-springs (Figure 6A
Figure 5 Loss of APOBEC3 gene enhances sexual transmission of LP-BM5 virus. Age and weight-matched WT, mA3+/-, and mA3-/- male
(♂) mice on C57BL/6 background (n = 5) were inoculated with LP-BM5 virus via the IP route. Four weeks after infection, mice were mated for
6 days (normal estrus cycle in laboratory mouse) with age and weight-matched WT, mA3+/-, and mA3-/- female (♀) mice on C57BL/6
background (n = 3). Female mice were removed from their male partners, housed separately, and pregnancy status determined to ensure mating.
Male mice were sacrificed upon removal of female partners (five weeks post infection). All female mice were bled on day 12 following mating to
obtain peripheral blood mononuclear cells (PBMCs) and then sacrificed. Upon necropsy, the testes and spleen were collected from male mice
and spleen from female mice. DNA was extracted from all samples. Rate of male mice infection was examined by examining level of viral DNA
present in testes (A) and spleen (B). Rate of virus transmission was determined by evaluating level of viral DNA present in spleen (C to E) and
PBMCs (F to H) of female mice of different genotypes mated to male mice of different genotypes. Side-by-side comparison of sexual virus
transmission from WT, mA3+/-, or mA3-/- infected male to a WT female is shown for spleen (I) and PBMCs (J). Error bars are standard error; * is
significance with p value equal or less than 0.05; and ** is significance with p value equal or less than 0.01. Experiments were performed at least
three different times with similar results. ♂=male, ♀= female.
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female (Figure 6B ♂ and ♀) show significantly higher
levels of infection compared to their mA3 +/- litter
mates (Figure 6A bars 1, 3, 4 and 6B lanes 1, 3, 4). Simi-
lar observations were made on 1) mA3-/- off-spring(Figure 6D bar 3) from mA3+/- male and mA3-/- female
(Figure 6E ♂ and ♀) compared to its mA3 +/- litter
mates (Figure 6D bars 1, 2, 4, 5 and 6E lanes 1, 2, 4, 5);
2) mA3+/- off-spring (Figure 6G bars 1, 4 and Figure 6H
lanes 1, 4) from mA3+/- male and mA3+/+ female
Table 1 mA3 genotype permutation for the generation of off-springs from parents of different genetic backgrounds
Male (♂) Female (♀) Off-spring mA3 genotype
mA3 genotype mA3 genotype 1 2 3 4 5
♂ 159 -/- ♀ 159C +/- +/- -/- +/- +/-
♂ 160 +/- ♀ 160C -/- +/- +/- -/- +/- +/-
♀ 160D WT +/- WT WT +/- WT
♂ 161 WT ♀ 161D +/- +/- +/- WT WT +/-
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ter mates (Figure 6G bars 2, 3, 5 and Figure 6H lanes
2, 3, 5); and 3) mA3+/- off-spring (Figure 6J bars 1, 2,Figure 6 Susceptibility of off-spring of sexually infected mothers to L
+/-, and mA3-/- male (♂) mice on C57BL/6 background (n = 5) were inocul
mice were mated (Table 1) for 6 days with age and weight-matched WT, m
Female mice were removed from their male partners, housed separately th
to nurse the off-spring for 3 days and female mice and her off-springs wer
were collected. Mammary gland tissues from all female mice were also col
described [47]. DNA was extracted from spleen and used to determine leve
(B, E, H, K). Total RNA was extracted from milk samples and mammary gla
mammary gland viral load (M). Error bars are standard error; * is significanc
p value equal or less than 0.01. Experiments were performed three differen5 and Figure 6K lanes 1, 2, 5) from WT male and
mA3+/- female (Figure 6K ♂ and ♀) compared to
their WT litter mates (Figure 6J bars 3, 4 andP-BM5 is APOBEC3-dependent. Age and weight-matched WT, mA3
ated with LP-BM5 virus via the IP route. Four weeks after infection,
A3+/-, and mA3-/- female (♀) mice on C57BL/6 background (n = 3).
roughout the gestation period. Upon parturition, mice were allowed
e euthanized. The spleens of all mice (male, female, and off-spring)
lected, and milk from individual off-spring was obtained as previously
l of off-spring infection (A, D, G, J) and genotype of all mice
nd tissues and used to determine milk viral load (C, F, I, L) and
e with p value equal or less than 0.05; and ** is significance with
t times with similar results. ♂=male, ♀= female.
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ences were off-spring-mA3 gene dependent, we exam-
ined the level of vRNA in milk consumed by each
off-spring from the same sexually infected female. Our
results indicate no differences in milk vRNA among off-
springs from the same female (Figures 6C, 6F, 6I, 6L);
however, differences abound in the amount of vRNA
that females of different genotype harbor in their mam-
mary gland tissues, and these differences correlate with
the female mA3 genotype (Figures 6M). The fact that
off-springs of sexually infected female mice were
infected serve as a validation of sexual virus transmis-
sion from an infected male to the female counterpart.
Variation in infection level observed between pups
from different parents could stem from a number of
factors, including genetic disposition of the pup with
respect to different genes or related factors, amount of
virus in mother’s milk, rate of virus acquisition by in-
dividual pups - which could be influenced by the
amount of milk consumed by the pup, as well as the
amount of virus in mothers milk.
Genital organ mA3 determines susceptibility to sexual
transmission
We have shown that mA3 is expressed in male genitalia
(Figure 1A and 1B) and that viral load in the genitalia
organs is higher in mA3-/- mice (Figure 4F). Based on
these data, we hypothesize that the higher rate of virus
transmission from mA3-/- infected males to their naïve
female partners is mediated by genitalia intrinsic mA3.
Hence, we used adoptive transfer experiments to create
mA3-/- mice that lack mA3 in the genital organs but ex-
press mA3 in their lymphocytes, and the control mice
that are mA3 deficient in both genital organs and lym-
phocytes (Figure 7A). Results show that mA3-/- mice
with WT stem cells show significantly lower splenocyte
infection compared to the control mice with mA3-/-
stem cells (Figure 7B), indicating that mA3-/- spleno-
cytes are more susceptible to infection. Comparison of
genital organs (testes, epididymis, and seminal gland) in-
fection from these mice reveals no differences in level of
infection (Figures 7C to 7E). To determine whether
mA3 intrinsically expressed in genital organs or lympho-
cytes is responsible for restricting sexual virus transmis-
sion, we mated naïve WT female mice with the above
males (mA3-/- males with WT or mA3-/- cells). Con-
trary to our observation of male infection, splenocytes
and mammary gland of female mice mated with and
sexually infected by males that received WT or mA3-/-
cells have similar levels of infection (Figure 7F and 7G)
indicating that the male genital environment controls
virus transmission. Examination of the generation 1
(F1 – mA3+/-) off-springs of mA3-/- males and WT
females at 4 and 13 weeks post parturition also reveal nodifferences in splenic viral load (Figure 7H and 7I). These
genetic data suggest that genitalia-intrinsic mA3 is import-
ant and mediates restriction of sexual virus transmission.
Discussion
HIV is mostly propagated worldwide through sexual
transmission. While a number of host factors have been
identified to enhance sexual transmission of HIV [74],
factors that limit sexual transmission of HIV have not
been described. However, APOBEC3 as an anti-HIV fac-
tor that restricts infection of hematopoietic and non-
hematopoietic cells [47,50] could potentially play a role
in sexual transmission. Recently, in vivo studies in mice
show that APOBEC3 restricts MMTV infection of the
lymphoid compartment, resulting in lower levels of virus
infection in mammary tissue, accompanied by a decreased
rate of milk-borne transmission of MMTV [47].
Here, we demonstrate a possible role for APOBEC3 in
restricting a sexually transmitted virus infection. We
show that mice with targeted deletion of the Apobec3
gene have higher rates of LP-BM5 infection in lymphoid
and genital tissues, and that this results in enhanced
rates of sexual transmission of LP-BM5 virus. It is
known that LP-BM5 infects genital tissues [73] and
causes severe immunodeficiency and splenomegaly [18-
22]. APOBEC3 is made in genital organs; interestingly,
the absence of APOBEC3 in these organs, as in APO-
BEC3 knockout mice, altered infection of the genital
organs. Higher level of infection in APOBEC3 knockout
mice provides evidence that APOBEC3 mediates the
susceptibility of the genitalia and gametes to virus infec-
tion. Additionally, the significantly higher vRNA in geni-
tal organs of APOBEC knockout mice (Figure 4I), as
well as high levels of extracellular vRNA and protein in
seminal plasma (Figure 4E and 4G) from APOBEC3
knock mice indicates that LP-BM5 is actively replicating
more efficiently in the absence of APOBEC3. Our find-
ing is in line with published reports [75,76] which
showed the occurrence of active virus replication in
semen of HIV-1 infected men. The alteration of virus in-
fection in genital compartment in APOBEC3 knockout
mice positively correlates with high level of viral RNA in
seminal plasma, as well as increased infectivity of sem-
inal plasma LP-BM5 virus compared to wild type mice.
The demonstration that extracellular virions from sem-
inal plasma obtained from APOBEC3 knockout mice are
more infectious than that from control mice further
confirms that loss of mA3 results in higher virus load
(Figure 4H). These results suggest that genital organ-
intrinsic APOBEC3 expression serves to limit sexual
transmission of LP-BM5, and perhaps other retroviruses.
Indeed, we show that seminal fluid of APOBEC3 knock
mice harbors more LP-BM5 virus compared to the wild
type as visualized by Western blot (Figure 4G), but we
Figure 7 Susceptibility of mice to sexual transmission of LP-BM5 is dependent on mA3 expressed in genitalia. Age and weight-matched
mA3-/- male (♂) mice on C57BL/6 background (n = 6) were lethally irradiated, reconstituted with bone marrow stem cells from WT or mA3 -/-
mice, infected with LP-BM5 virus, and mated with naïve WT females (♀) for six days. Male mice were sacrificed at the end of mating. Female
mice were allowed to nurse the resultant off-springs (heterozygotes) for three weeks. Off-springs were divided into two groups, and the first
group were sacrificed at four week and the second group at thirteen weeks post-parturition (A). Spleen, testes, epididymis, and seminal gland
were obtained from male mice and used for DNA extraction and examination of infection level by qPCR (B to E). Spleen and mammary gland
tissues were obtained from female mice and used to evaluate rate of virus transmission by qPCR (F and G). Spleen tissues from the off-springs
were used to examine rate of virus transmission from the infected mother (H and I). Error bars are standard error; ** is significance with p value
equal or less than 0.01. This experiment was repeated 2 additional times with similar results. ♂=male, ♀= female.
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of good anti-mouse APOBEC3 antibodies or limited viral
protein in samples from APOBEC3 sufficient mice. The
detection of LP-BM5 proviral DNA in spermatozoa and
testes support previous observations made with HIV-1
and herpesvirus type 8 [77-80].Using genetic studies, we found that APOBEC3 med-
iates rate of sexual transmission of LP-BM5. The differ-
ent permutations of genetic backgrounds used clearly
show that the APOBEC3 gene is critical in determining
the outcome of sexual transmission of LP-BM5 from
one partner to the other, and from a sexually infected
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of APOBEC3 enhanced rate of sexual transmission, we
also observed that APOBEC3 deficient female mice were
more highly infected compared to the heterozygote and
wild type controls in that order. These genetic experi-
ments show that APOBEC3 also plays a crucial role in
mediating virus acquisition from an infected male and
that the female genetic background contributes in defin-
ing the outcome of infection.
We also used adoptive transfer and in vivo genetic
experiments to demonstrate a clear relationship between
genital-intrinsic APOBEC3 and sexual transmission.
Genital-intrinsic APOBEC3 mediates control of sexual
transmission since higher levels of splenocyte infection
observed in male mice that received APOBEC3 knock-
out cells did not translate to higher rate of female part-
ner infection. This concept was further confirmed by
similar level of infection observed in the off-springs of
these mice irrespective of the male parent splenocyte
APOBEC3 genotype.
While murine retroviruses (beta and gamma retro-
viruses) are sensitive to A3 antiviral activity, they have
also successfully replicated in mice. It is not clear how
these infectious viruses have evaded host restriction to
achieve efficient replication, since they do not encode
viral accessory proteins, such as the HIV-1 Vif protein
that antagonizes some human A3 proteins. However,
reports of alternative mechanisms used by murine retro-
viruses to evade restriction by A3 proteins exist. Indeed,
MLV virions have been shown to exclude mA3 [81] as
well as inactivate mA3 by viral protease [82], and xeno-
tropic murine leukemia-virus related virus (XMRV)
down-regulates hA3G in prostate cancer cells [83].
Sexual transmission of HIV-1 continues to be a prob-
lem worldwide, especially in developing countries, where
access to condoms is restricted by cultural and socio-
economic situations. Previous studies have indicated that
the use of HAART in the control of HIV transmission
has mixed results since some HAART treated patients
with suppressed plasma viral load continue to shed viral
RNA in semen [12,13].Conclusion
As in immune cells and mammary epithelia cells, APO-
BEC3 is made in genital organs and gametes. Based on
our data, we suggest that APOBEC3 expression in geni-
tal organs and gametes may have been retained as a
means of inhibiting sexual transmission of viruses. In
addition, APOBEC3 in genital organs could have import-
ant therapeutic implications for sexual transmission of
viruses. For example, therapeutics could be developed
that increase APOBEC3 level in genital organs, resulting
in attenuated virions.Methods
Ethics statement
Experiments involving the use of mice were performed
in accordance to NIH guidelines, the Animal Welfare
Act, and US federal law. Experiments were approved by
the University of Iowa Animal Care and Use Committee
(IACUC).Cells
MEF and primary testicular cells were obtained from
mA3-/-, mA3+/-, and WT mice on C57BL/6 back-
ground. SC1-G6 cells chronically infected with LP-BM5
(containing ecotropic, mink cell focus-forming and de-
fective viruses) were obtained through the AIDS Re-
search and Reference Reagent Program, Division of
AIDS, NIAID, NIH from Dr. Herbert Morse and Dr.
Janet Hartley [15,19,23].Mice
The mA3-knockout (mA3-/-) and matched controls
mA3+/-, (mA3+/+, WT) mice have been previously
described [45]. All mice were housed according to the
policies of the Institutional Animal Care and Use Com-
mittee of the University of Iowa.Adoptive transfer
Five age-matched (5 weeks old) male mice of each geno-
type were lethally irradiated with gamma rays. All radi-
ation experiments were performed at the Radiation and
Free Radical Research Core Facility of the University of
Iowa. Mice were irradiated with a dose of 9 Gy (dose
rate, 0.345 Gy/min) using a 137Cs source (JL Shepherd,
San Fernando, CA) as previously described [47]. Four
hours after irradiation, mice were reconstituted with
bone marrow stem cells from either mA3-/- or WT
mice. Four weeks after reconstitution, the mice were
inoculated with LP-BM5 virus. Prior to infection, periph-
eral blood lymphocytes from each mouse were subjected
to FACs analysis with conjugated anti-mouse CD8, CD4,
CD11c and B220, to test for uniform reconstitution.Virus propagation
Cell-free LP-BM5 viral mixture was prepared from
chronically infected SC-l cells as previously described
[84]. Culture supernatants were collected and centri-
fuged at 1500 rpm for 10 minutes to clarify cellular deb-
ris. Clarified culture supernatants were filtered through
a 0.45 μM filter, layered on to 20% sucrose cushion and
centrifuged at 7000 rpm, 4 °C overnight. Virus pellet was
resuspended in PBS at 10:1 ratio and aliquots of 100 μl
stored at -80 °C until required for use.
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Infection of cells with cell culture or seminal plasma
virus was done in triplicates in 96-well plate format.
Briefly, primary testicular cells or splenocytes were pla-
ted at ~100,000 cells per well. Twenty four hours later,
cells were incubated with 8 μg/ml of polybrene for 2
hours. Polybrene-containing medium was removed and
replaced with 100 μl of virus-containing medium or PBS
for control. Cells were spinoculated at 1200 rpm for 2
hours at room temperature. Following spinoculation,
cells were incubated at 37 °C for 24 hours. DNA was
extracted from cells for examination of viral load. Mice
infections were done either subcutaneously (SubQ) on
the hind footpad or intraperitoneally (IP). For footpad
inoculation, 30 μl of virus or PBS was injected into the
footpad tissue and IP inoculation was performed with
200 μl of virus or PBS. At the appropriate time depend-
ing on experiment, mice were sacrificed and relevant tis-
sues obtained for downstream analysis.
Genotyping mA3 -/- mice
Mice genotypes were determined using two parallel
PCRs as previously described [45]. Briefly, DNA was
extracted and 50 ng of genomic DNA and 25 pmol of
primers were used in a total volume of 25 μl PCR reac-
tion. PCR amplicons were separated on a 2% agarose gel.
Nucleic acid isolation and real-time quantitative PCR
Milk and seminal plasma viral loads were determined
for BM5def as previously described [85]. Briefly, total
RNA was isolated from seminal fluid (200 μl) or milk
(50 μl) samples using Trizol RNA Reagent (AMRESCO).
Isolated RNA was DNAsed and subjected to cDNA syn-
thesis (Applied Biosystems, ABI) as previously described
[86]. DNA was also isolated from different tissues using
QIAGEN-QIAamp DNA Mini Kit following manufac-
turer’s recommendation. Nucleic acid concentration and
purity were measured spectrophotometrically at 260/
280 nm. DNA and cDNA were amplified with primers
and probe specific to BM5def [87] and GAPDH using
ABI 7500 FAST thermal cycler (ABI).
Flow cytometry
Approximately, 1 × 106 splenocytes were stained in PBS +
1% bovine serum albumin (Sigma-Aldrich) for 30 min-
utes on ice with APC-, FITC-, and PE-conjugated anti-
bodies and the resulting immunofluorescence was
analyzed by use of a FACSCalibur flow cytometer (BD)
to detect the expression of murine CD69, B220, and
CD4 (BD or eBioscience). Cellular frequency and fluor-
escence intensity were determined by Flowjo analysis
software (TreeStar). APC-, FITC-, and PE-conjugated Ig
isotypes of irrelevant specificity were used as control for
each monoclonal antibody.Western blot
Western blots of virus preparations and cell extracts
were probed with anti-p30 (MLV capsid) and anti-
GAPDH. The species-appropriate IRDye secondary anti-
bodies were used, followed by detection with the
Odyssey Infrared Imaging System (LI-COR Biosciences).Virus purification from seminal plasma
The seminal samples obtained from epididymis were
processed immediately and pooled within genotype to
provide sufficient seminal plasma volume and seminal
cells. Pooled epididymal seminal samples were centri-
fuged for 15 minutes at 400 g. The pellet was further
purified to obtain pure sperm cells as discussed below.
The supernatant was collected and filtered through a
0.45 μM filter. Virions were purified from the superna-
tants by ultracentrifugation at 40,000 rpm for 30 min-
utes. Viral pellet was resuspended in PBS and stored in
50 μl aliquots at -80 °C until required for use.Spermatozoa purification
Pooled epididymal seminal samples were subjected to
standard swim-up technique to purify sperm cells.
Briefly, semen samples were centrifuged for 15 min at
400 g. The pellets were resuspended in pre-warmed
2.5 ml Ham's F-10 culture medium (Sigma) supplemen-
ted with 10% human serum albumin. Cells were layered
over equivalent volume of 80% Percoll and 40% Percoll
and centrifuged for 15 minutes at 400 g as previously
described [88]. The supernatant was discarded and the
pellet was resuspended in Ham's F-10 culture medium
and thereafter centrifuged for 15 minutes at 400 g. The
supernatant was removed and the pellet was overlaid
with 2.5 ml Ham's F-10 medium and incubated for
60 min in 5% CO2 at 37 °C to allow spermatozoa to
swim up from the pellet. A sterile Pasteur pipette was
used to remove the supernatant containing actively mo-
tile sperms. A drop of the sample was examined under
light microscope and images acquired with Nikon
Eclipse Ti (Nikon Instruments). Purified cells were
stored at -80 °C until required.Statistical analysis
The paired two-tailed Student's t test was used for statis-
tical analysis and a p value of 0.05 was considered sig-
nificant. Error bars represent standard deviations.
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